Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Manifold Bio gets $40 million for in vivo biologics design
by Gina Vitale
July 23, 2022
| A version of this story appeared in
Volume 100, Issue 26
Manifold Bio, a Boston-based start-up spun out of George Church’s lab at Harvard University and the Wyss Institute for Biologically Inspired Engineering, has raised $40 million in series A funding. Manifold says it has developed a system in which potential protein-based drugs can be tested in vivo as soon as they are designed rather than later in the development process. Manifold says its approach is powered by a bar-coding technology that allows protein mixtures to be tracked throughout testing.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter